<u>AMENDMENTS TO THE CLAIMS</u>

This listing of claims will replace all prior versions and listing of claims in the application.

1-22. (Cancelled)

23. (Previously presented) A composition comprising:

    (a)   a population of neural cells enriched for neurosphere initiating stem cells (NS-IC) produced by:

        (1)   combining a population comprising neural cells or neural-derived cells containing a fraction of NS-ICs with monoclonal antibody AC133 or monoclonal antibody 5E12; and

        (2)   selecting and isolating those cells that bind to monoclonal antibody AC133 or monoclonal antibody 5E12, thereby producing a population of cells enriched for NS-IC as compared with the population of neural cells or neural-derived cells; and

    (b)   at least one monoclonal antibody selected from the group consisting of monoclonal antibody AC133 and monoclonal antibody 5E12.

24.-26. (Cancelled)

27. (Previously presented) An *in vitro* cell culture composition comprising:

    (a)   a population of neural cells enriched in NS-IC, wherein the NS-IC bind to monoclonal antibody AC133 or to monoclonal antibody 5E12 and are CD45⁻ cells;

    (b)   a medium capable of supporting the growth of the cells; and

    (c)   at least one monoclonal antibody selected from the group consisting of monoclonal antibody AC133 and monoclonal antibody 5E12.

28. (Previously presented) An *in vitro* cell culture composition comprising:

(a) a population of neural cells enriched in NS-IC, wherein the NS-IC bind to monoclonal antibody AC133 or to monoclonal antibody 5E12 and are CD45$^-$ CD34$^-$cells;

(b) a medium capable of supporting the growth of the cells; and

(c) at least one monoclonal antibody selected from the group consisting of monoclonal antibody AC133 and monoclonal antibody 5E12.

29. (Currently amended) An *in vitro* cell culture composition comprising:

(a) a population of neural cells enriched in NS-IC, wherein the NS-IC bind to monoclonal antibody AC133 or to monoclonal antibody 5E12 and are CD24$^-$ cells;

(b) a medium capable of supporting the growth of the cells; and

(c) at least one monoclonal antibody selected from the group consisting of monoclonal antibody AC133 and monoclonal antibody 5E12.

30-31. (Cancelled)

32. (Previously presented) The composition of any one of claims 23 and 27-29, further comprising a solid support to which the cells are attached.

33. (Previously presented) The composition of any one of claims 23 and 27-29, wherein the population of cells comprises at least 70% cells that bind to monoclonal antibody AC133 or monoclonal antibody 5E12.

34. (Previously presented) The composition of any one of claims 23 and 27-29, wherein the population of cells comprises at least 90% cells that bind to monoclonal antibody AC133 or monoclonal antibody 5E12.

3

35. (Previously presented) The composition of any one of claims 23 and 27-29, wherein the population of cells that bind to monoclonal antibody AC133 or monoclonal antibody 5E12 is a substantially pure population.

36. (Previously presented) The composition of any one of claims 23 and 27-29, wherein the medium comprises a serum-free medium containing one or more growth factors effective for inducing multipotent neural stem cell proliferation.

37. (Previously presented) The composition of any one of claims 23 and 27-29, wherein the medium comprises a growth factor selected from the group consisting of leukocyte inhibitory factor (LIF), epidermal growth factor (EGF), basic fibroblast growth factor (FGF-2), and combinations thereof.

38. (Previously presented) The composition of any one of claims 23 and 27-29, wherein the medium comprises neural survival factor, NSF.

39. (Previously presented) The composition of any one of claims 23 and 27-29, wherein the neural cells are human.

40.-43. (Cancelled)